Oculomics using artificial intelligence derived retinal biomarkers for cardiovascular health
Sanghvi, Harshal A., Gill, Gurnoor S., Patel, Jay, Prasad, Minali, Khan, Najah, Sarup, Vimal, Gupta, Shailesh, Katariya, Kushagra, Bhavnani, Sanjeev P. npj Cardiovascular Health
· Springer Nature
· 2026-10-15
· DOI: 10.1038/s44325-026-00157-y
Abstract
This narrative review synthesizes evidence from retinal vascular morphology, structural and perfusion imaging, retinal aging, metabolomics, and artificial intelligence models linking retinal biomarkers with cardiovascular risk factors, subclinical disease, clinical events, and cardiorenal and metabolic outcomes. These biomarkers may complement conventional risk assessment, but clinical utility is unproven and integration into cardiovascular digital twins remains conceptual. Prospective validation, standardized acquisition, interoperability, interpretability, and equitable evaluation are required before implementation.
Sanghvi, Harshal A., Gill, Gurnoor S., Patel, Jay et al. Oculomics using artificial intelligence derived retinal biomarkers for cardiovascular health. // npj Cardiovascular Health. – 2026. – DOI: 10.1038/s44325-026-00157-y. – URL: https://doi.org/10.1038/s44325-026-00157-y
Sanghvi, Harshal A, Gill, Gurnoor S, Patel, Jay, Prasad, Minali, Khan, Najah, Sarup, Vimal, Gupta, Shailesh, Katariya, Kushagra, Bhavnani, & Sanjeev P (2026). Oculomics using artificial intelligence derived retinal biomarkers for cardiovascular health. npj Cardiovascular Health. https://doi.org/10.1038/s44325-026-00157-y
Sanghvi, et al. “Oculomics using artificial intelligence derived retinal biomarkers for cardiovascular health.” npj Cardiovascular Health, 2026. doi:10.1038/s44325-026-00157-y.
@article{Sanghvi2026,
title = {Oculomics using artificial intelligence derived retinal biomarkers for cardiovascular health},
author = {Sanghvi and A., Harshal and Gill and S., Gurnoor and Patel and Jay and Prasad and Minali and Khan and Najah and Sarup and Vimal and Gupta and Shailesh and Katariya and Kushagra and Bhavnani and P., Sanjeev},
journal = {npj Cardiovascular Health},
year = {2026},
doi = {10.1038/s44325-026-00157-y},
url = {https://doi.org/10.1038/s44325-026-00157-y}
}
Fibroblast growth factor 21 (FGF21) is a key regulator in metabolic diseases. Serum FGF21 levels are significantly elevated in patients with hyperuricemia and correlate positively with uric acid. In hyperuricemic mice, FGF21 is...
Artificial intelligence (AI) in cardiology is rapidly expanding, but enthusiasm for anticipated benefits should be balanced by a more critical inspection of ethical concerns. In this state-of-the-art review, we discuss the four pillars...
Acute stroke alerts are frequently activated for non-cerebrovascular conditions, creating false positives that strain resources and increase diagnostic uncertainty. We developed machine learning models integrating large-language models,...
Circadian imbalance may contribute to hypertension, but its association with incident hypertension, genetic susceptibility, and molecular pathways remains unclear. This prospective study included 107,270 UK Biobank participants free of...
Traditional 12-lead ECGs offer comprehensive insights into the electrical activity of the heart, but require clinical settings and expert interpretation, which limits their accessibility. Smartwatch 1-lead ECGs can be recorded at home,...